Literature DB >> 3041124

Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group.

.   

Abstract

The disease-free, postresection, 2 year survival rate of patients with T1 N0 non-small cell lung cancer surgically/pathologically staged by the Lung Cancer Study Group is about 82%. This study of the rate of cancer recurrence and histopathologic types is based on 572 eligible patients who submitted to complete resection of T1 N0 lung cancer and rigorous, systematic mediastinal lymph node sampling. The initial pathologic interpretation and staging were reviewed by pathologists of the Lung Cancer Study Group Pathology Reference Center to assure uniformity. Review was completed for 82% of patients included in this report. Postoperative cancer recurrence was observed in 107 of the 572 eligible patients. Histopathologic classification was squamous carcinoma (226 patients) or nonsquamous, non-small cell carcinoma (346 patients). Cancer recurrences are more frequent and recurrence rates are higher in the patients with nonsquamous cancer. There is a greater probability of first recurrence in the brain in the nonsquamous carcinoma group. This study substantiates the observation that lung cancer recurrences are histopathologically dependent in the T1 N0 subgroup of Stage I non-small cell lung cancer, with higher rates occurring among patients with nonsquamous carcinoma.

Entities:  

Mesh:

Year:  1987        PMID: 3041124

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in lung adenocarcinoma.

Authors:  José Manuel Ruiz-Morales; Rita Dorantes-Heredia; Oscar Arrieta; Norberto C Chávez-Tapia; Daniel Motola-Kuba
Journal:  Tumour Biol       Date:  2014-12-27

2.  Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma.

Authors:  M Wislez; J Fleury-Feith; N Rabbe; J Moreau; D Cesari; B Milleron; C Mayaud; M Antoine; P Soler; J Cadranel
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

3.  Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population.

Authors:  Edmund S Kassis; Ara A Vaporciyan; Stephen G Swisher; Arlene M Correa; B Nebiyou Bekele; Jeremy J Erasmus; Wayne L Hofstetter; Ritsuko Komaki; Reza J Mehran; Cesar A Moran; Katherine M Pisters; David C Rice; Garrett L Walsh; Jack A Roth
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05-28       Impact factor: 5.209

4.  Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer.

Authors:  E R Gritz; R Nisenbaum; R E Elashoff; E C Holmes
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

5.  Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.

Authors:  Ana Belén Custodio Carretero; José Angel García Sáenz; José Luis González Larriba; Jana Bobokova; Antonio Calles Blanco; Florentino Hernando Trancho; Beatriz García Paredes; Laura Rodríguez Lajusticia; Eduardo Díaz-Rubio García
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

6.  Incidence and patterns of isolated brain failure in stage III non-small-cell lung cancer treated with concurrent chemoradiation therapy.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Takatoshi Senba; Kotaro Uwatsu; Shogo Oda; Tadaaki Takahashi; Shoji Aono; Shinya Sakai; Takeshi Inoue; Yoshifumi Sugawara
Journal:  Jpn J Radiol       Date:  2009-02-08       Impact factor: 2.374

7.  [Analysis of Survival Predictors in Patients with Lung Cancer and Brain Metastases].

Authors:  Shaohua Cui; Hao Bai; Lili Dong; Yizhuo Zhao; Aiqin Gu; Wei Zhang; Yuqing Lou; Liyan Jiang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-07

8.  Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer.

Authors:  Hasan Mutlu; Abdullah Büyükçelik; Eser Kaya; Mustafa Kibar; Ertuğrul Seyrek; Sinan Yavuz; Züleyha Calikuşu
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.